Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models

Thierry Bouyssou(Boehringer Ingelheim (Germany)), Paola Casarosa(Boehringer Ingelheim (Germany)), Emmanuel Naline(Hôpital Foch), Sabine Pestel(Hôpital Foch), Ingo Konetzki(Hôpital Foch), P. Devillier(Hôpital Foch), A. Schnapp(Boehringer Ingelheim (Germany))

Journal of Pharmacology and Experimental Therapeutics

April 7, 2010

10.1124/jpet.110.167007

Cited by 116

Abstract

Related Papers

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi Cheng, William H. Prusoff|Biochemical Pharmacology|1973|12.9k

The Global Burden of Asthma

Sidney S. Braman|CHEST Journal|2006|1.2k

Burden and clinical features of chronic obstructive pulmonary disease (COPD)

Romain Pauwels, Klaus F. Rabe|The Lancet|2004|1k

Principles: Receptor theory in pharmacology

Terry Kenakin|Trends in Pharmacological Sciences|2004|410

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

Christine Jenkins, Paul Jones, Peter M.A. Calverley et al.|Respiratory Research|2009|344